Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis

BACKGROUND: According to available research, there have been no head-to-head studies comparing the effect of glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors on cardiovascular outcomes among patients with type 2 diabetes not reaching glycemic goal with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yeong-Min, Lee, Soon-Hee, Kim, Tae-Hee, Park, Eun-Ji, Park, Young-Ah, Jang, Jae-Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2022
Materias:
Clinical Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170323/
https://www.ncbi.nlm.nih.gov/pubmed/33140391
http://dx.doi.org/10.5603/CJ.a2020.0140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170323/
https://www.ncbi.nlm.nih.gov/pubmed/33140391
http://dx.doi.org/10.5603/CJ.a2020.0140

Ejemplares similares